← Human Trials & Peer-Reviewed Studies
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
Plain-language guide to NCT07091734: phase 2 randomized trial of Tirzepatide, 32 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT07091734
- Phase
- phase 2
- Status
- recruiting participants
- Start
- 2025-09-08
- Completion (planned or actual)
- 2029-09
- Participants
- 32 (estimated)
- Design
- randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Lipodystrophy, Partial
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered phase 2 trial tested Tirzepatide.
It had two arms (groups): Tirzepatide then usual care (Group A) (experimental) and Usual care treatment then Tirzepatide (Group B) (experimental).
The registry classes the interventions as drug.
Who Took Part
32 planned participants were the target.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers were not accepted; participants needed the condition being studied.
The full record lists 6 inclusion and 22 exclusion criteria; among the exclusions: diagnosis of generalized lipodystrophy or acquired lipodystrophy; having received treatment with a glucagon-like peptide (glp) -1 agonist or tirzepatide within the past 6 months; history of previous treatment with metreleptin within the past 3 months.
How the Study Was Run
Design: randomized, crossover and open-label.
Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In the crossover set-up each of the participants took both Tirzepatide and the comparison in turn, acting as their own control.
Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.
It started in 2025-09-08 with completion listed for 2029-09.
It ran at 1 site in United States.
Its stated primary purpose is treatment.
What Was Measured
The main thing measured (primary outcome): Change in Body Mass Index (BMI) from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks (time frame: Baseline, 24 weeks). Change in Hemoglobin A1c from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks (time frame: Baseline, 24 weeks).
What This Means in Plain Language
Put simply, this is a phase 2, randomized trial of Tirzepatide in 32 people.
Its size is small, so on its own it can only give an early look.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Tirzepatide compound page, all human trials.
Our Notes on the Compound
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.